Cangrelor in percutaneous coronary intervention

Expert Review of Clinical Pharmacology

Volumn 2, Issue 2, 2009, Pages 137-145

  Oestreich, Julie H ^a   Steinhubl, Steven R ^b,c  

^a University of Kentucky   (United States)

^b GEISINGER MEDICAL CENTER   (United States)

^c Medicines Company   (Switzerland)

Author keywords

Acute coronary syndrome; Cangrelor; Clopidogrel; P2Y12 receptor; Percutaneous coronary intervention; Platelet inhibition

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; CANGRELOR; CLOPIDOGREL; HEPARIN; PLACEBO;

ADJUVANT THERAPY; ARTICLE; BLEEDING; BOLUS INJECTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; LOADING DRUG DOSE; MONOTHERAPY; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS;

EID: 70249088025     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/17512433.2.2.137     Document Type: Article

References (44)

1. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345(7), 494-502 (2001).
2. Steinhubl SR, Berger PB, Mann JT 3rd et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288(19), 2411-2420 (2002).
3. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348(9038), 1329-1339 (1996).
4. Chen ZM, Jiang LX, Chen YP et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366(9497), 1607-1621 (2005).
5. Sabatine MS, Cannon CP, Gibson CM et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med. 352(12), 1179-1189 (2005).
6. Steinhubl SR, Berger PB, Brennan DM, Topol EJ. Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. J. Am. Coll. Cardiol. 47(5), 939-943 (2006).
7. von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati A, Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose between 3 High Oral Doses for Immediate Clopidogrel Effect) trial. Circulation 112(19), 2946-2950 (2005).
8. Yusuf S, Mehta SR, Zhao F et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 107(7), 966-972 (2003).
9. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 117(2), 261-295 (2008).
10. Bassand JP, Hamm CW, Ardissino D et al. Guidelines for the diagnosis and reatment of non-ST-segment elevation acute coronary syndromes. Eur. Heart J. 28(13), 1598-1660 (2007).
11. Van de Werf F, Bax J, Betriu A et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the management of ST-segmeht elevation acute myocardial infarction of the European Society of Cardiology. Eur. Heart J. 29(23), 2909-2945 (2008).
12. Ding Z, Kim S, Dorsam RT, Jin J, Kunapuli SP. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood 101(10), 3908-3914 (2003).
13. Kunapuli SP, Ding Z, Dorsam RT, Kim S, Murugappan S, Quinton TM. ADP receptors - targets for developing antithrombotic agents. Curr. Pharm. Des. 9(28), 2303-2316 (2003).
14. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Variability in individual responsiveness to clopidogrel: clinical implications management, and future perspectives. J. Am. Coll. Cardiol. 49(14), 1505-1516 (2007).
15. Yang EH, Gumina RJ, Lennon RJ, Holmes DR Jr, Rihal CS, Singh M. Emergency coronary artery bypass surgery for percutaneous coronary interventions: changes in the incidence, clinical characteristics, and indications from 1979 to 2003. J. Am. Coll. Cardiol. 46(11), 2004-2009 (2005).
16. Mehta RH, Chen AY, Pollack CV Jr et al. Challenges in predicting the need for coronary artery bypass grafting at presentation in patients with non-ST-segment elevation acute coronary syndromes. Am. J. Cardiol. 98(5), 624-627 (2006).
17. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J. Am. Coll. Cardiol. 45(2), 246-251 (2005).
18. Mobley JE, Bresee SJ, Wortham DC, Craft RM, Snider CC, Carroll RC. Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. Am. J. Cardiol. 93(4), 456-458 (2004).
19. Bonello L, Camoin-Jau L, Arques S et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J. Am. Coll. Cardiol. 51(14), 1404-1411 (2008).
20. Barragan P, Bouvier JL, Roquebert PO et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc. Interv. 59(3), 295-302 (2003).
21. Matetzky S, Shenkman B, Guetta V et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute miyocardial infarction. Circulation 109(25), 3171-3175 (2004).
22. Cuisset T, Frere C, Quilici J et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J. Thromb. Haemost. 4(3), 542-549 (2006).
23. Heestermans AA, van Werkum JW, Taubert D et al. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb. Res. DOI: 10.1016/ j.thromres.2008.01.021 (2008).
24. Gladding P, Webster M, Ormiston J, Olsen S, White H. Antiplatelet drug nonresponsiveness. Am. Heart J. 155(4), 591-599 (2008).
25. Jakubowski JA, Payne CD, Li YG et al. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. Thromb. Haemost. 99(1), 215-222 (2008).
26. Wallentin L, Varenhorst C, James S et al. Prasugrel achieves greater and faster P2Y12 eceptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur. Heart J. 29(1), 21-30 (2008).
27. Brandt JT, Payne CD, Wiviott SD et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am. Heart J. 153(1), E66-E69 (2007).
28. Jernberg T, Payne CD, Winters KJ et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur. Heart J. 27(10), 1166-1173 (2006).
29. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357(20), 2001-2015 (2007).
30. Angiolillo DJ, Capranzano P. Pharmacology of emerging novel platelet inhibitors. Am. Heart J. 156(2 Suppl.), S10-S15 (2008).
31. van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin. Thromb. Hemost. 31(2), 195-204 (2005).
32. Ingall AH, Dixon J, Bailey A et al. Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. J. Med. Chem. 42(2), 213-220 (1999).
33. Hollopeter G, Jantzen HM, Vincent D et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409(6817), 202-207 (2001).
34. 2 receptor in platelet activation. J. Clin. Invest. 113(3), 340-345 (2004).
35. Data on file with The Medicines Company.
36. Marcus AJ, Broekman MJ, Drosopoulos JH et al. Metabolic control of excessive extracellular nucleotide accumulation by CD39/ ecto-nucleotidase-1: implications for ischemic vascular diseases. J. Pharmacol. Exp. Ther. 305(1), 9-16 (2003).
37. Fugate SE, Cudd LA. Cangrelor for treatment of coronary thrombosis. Ann. Pharmacother. 40(5), 925-930 (2006).
38. Jacobsson F, Swahn E, Wallentin L, Ellborg M. Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction. Clin. Ther. 24(5), 752-765 (2002).
39. 12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. Am. Heart J. 154(4), 702-709 (2007).
40. 12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, Phase II, multicenter, randomized, placebo- and active-controlled trial. Am. Heart J. 151(3), 689E1-689E10 (2006).
41. Storey RF, Oldroyd KG, Wilcox RG. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb. Haemost. 85(3), 401-407 (2001).
42. Steinhubl SR, Oh JJ, Oestreich JH, Ferraris S, Charnigo R, Akers WS. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb. Res. 121(4), 527-534 (2008).
43. Dovlatova NL, Jakubowski JA, Sugidachi A, Heptinstall S. The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J. Thromb. Haemost. 6(7), 1153-1159 (2008).
44. Angiolillo DJ, Guzman LA. Clinical overview of promising nonthienopyridine antiplatelet agents. Am. Heart J. 156(Suppl. 2), S23-S28 (2008).